![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EU Purchases 160 Million Doses of Moderna’s COVID-19 Vaccine
EU Purchases 160 Million Doses of Moderna’s COVID-19 Vaccine
![Vaccine needle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Vaccine-needle-bottle.gif?t=1596243581&width=430)
November 25, 2020
The European Commission has signed an agreement with Cambridge, Mass.-based Moderna for up to 160 million doses of its COVID-19 vaccine candidate, mRNA-1273, which has demonstrated 94.5 percent efficacy in a phase 3 clinical trial.
This marks the sixth advance purchase agreement the EU has signed for a COVID-19 vaccine. It has also struck deals with AstraZeneca, Pfizer/BioNTech, Sanofi/GlaxoSmithKline, Johnson & Johnson and CureVac.
Financial terms of the EU contract were not disclosed, but Moderna CEO Stephane Bancel said the company planned to charge governments between $25 and $37 per dose.
Upcoming Events
-
21Oct